Sakar Healthcare Limited (SAKAR.NS)
INR 258.29
(6.94%)
INR 258.29
(6.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 790.93 Million INR | -28.84% |
| 2022 | 1.11 Billion INR | 19.73% |
| 2021 | 928.31 Million INR | 118.35% |
| 2020 | 425.14 Million INR | 159.21% |
| 2019 | 164.01 Million INR | 44.04% |
| 2018 | 113.86 Million INR | -19.72% |
| 2017 | 141.83 Million INR | -40.94% |
| 2016 | 240.14 Million INR | 9.72% |
| 2015 | 218.87 Million INR | -15.64% |
| 2014 | 259.46 Million INR | -1.14% |
| 2013 | 262.46 Million INR | -9.02% |
| 2012 | 288.48 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 835.54 Million INR | 0.0% |
| 2023 FY | 790.93 Million INR | -28.84% |
| 2023 Q1 | 35.22 Million INR | -96.83% |
| 2023 Q4 | 790.93 Million INR | 24921.73% |
| 2023 Q2 | 681.19 Million INR | 1833.79% |
| 2023 Q3 | 3.16 Million INR | -99.54% |
| 2022 Q2 | 1 Billion INR | 1312.95% |
| 2022 Q3 | 191.77 Million INR | -80.98% |
| 2022 Q1 | 71.35 Million INR | -92.31% |
| 2022 FY | 1.11 Billion INR | 19.73% |
| 2022 Q4 | 1.11 Billion INR | 479.6% |
| 2021 FY | 928.31 Million INR | 118.35% |
| 2021 Q4 | 928.31 Million INR | 458.07% |
| 2021 Q2 | 629.23 Million INR | 0.0% |
| 2021 Q3 | 166.34 Million INR | -73.56% |
| 2020 FY | 425.14 Million INR | 159.21% |
| 2020 Q1 | 2.96 Million INR | -98.2% |
| 2020 Q4 | 425.14 Million INR | 1097.83% |
| 2020 Q2 | 339.79 Million INR | 11379.49% |
| 2020 Q3 | 35.49 Million INR | -89.55% |
| 2019 Q4 | 164.01 Million INR | 266.67% |
| 2019 FY | 164.01 Million INR | 44.04% |
| 2019 Q1 | 3.66 Million INR | -96.78% |
| 2019 Q2 | 111.7 Million INR | 2945.5% |
| 2019 Q3 | 44.73 Million INR | -59.96% |
| 2018 Q1 | 3.62 Million INR | -97.45% |
| 2018 Q2 | 61.03 Million INR | 1584.64% |
| 2018 Q4 | 113.86 Million INR | 0.0% |
| 2018 FY | 113.86 Million INR | -19.72% |
| 2017 FY | 141.83 Million INR | -40.94% |
| 2017 Q4 | 141.83 Million INR | 0.0% |
| 2017 Q2 | 227.83 Million INR | 0.0% |
| 2016 Q4 | 207.75 Million INR | 0.0% |
| 2016 FY | 240.14 Million INR | 9.72% |
| 2015 Q1 | 255.3 Million INR | -1.61% |
| 2015 Q4 | 218.87 Million INR | 0.0% |
| 2015 Q2 | 255.3 Million INR | 0.0% |
| 2015 FY | 218.87 Million INR | -15.64% |
| 2015 Q3 | 218.87 Million INR | -14.27% |
| 2014 FY | 259.46 Million INR | -1.14% |
| 2014 Q4 | 259.46 Million INR | 0.0% |
| 2013 FY | 262.46 Million INR | -9.02% |
| 2012 FY | 288.48 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 79.541% |
| Hester Biosciences Limited | 2.29 Billion INR | 65.472% |
| Aarti Drugs Limited | 5.54 Billion INR | 85.745% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 69.718% |
| Albert David Limited | -278.36 Million INR | 384.133% |
| Alembic Limited | 66.9 Million INR | -1082.268% |
| Alkem Laboratories Limited | -1.6 Billion INR | 149.145% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -243.986% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 76.025% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 4387.851% |
| Brooks Laboratories Limited | 49.48 Million INR | -1498.337% |
| Eris Lifesciences Limited | 13.8 Billion INR | 94.271% |
| FDC Limited | -57.75 Million INR | 1469.54% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 127.824% |
| Gufic Biosciences Limited | 3.19 Billion INR | 75.239% |
| Hikal Limited | 7.96 Billion INR | 90.072% |
| Ind-Swift Limited | 9.5 Billion INR | 91.682% |
| Innova Captab Limited | 2.33 Billion INR | 66.109% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 171.818% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 156.905% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 97.078% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 719.672% |
| Lupin Limited | 19.38 Billion INR | 95.92% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 18.946% |
| Medico Remedies Limited | 78.67 Million INR | -905.296% |
| Morepen Laboratories Limited | -231.17 Million INR | 442.139% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 87.154% |
| Orchid Pharma Limited | -1.31 Billion INR | 160.2% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 133.686% |
| RPG Life Sciences Limited | -364.7 Million INR | 316.873% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -558.9% |
| Sigachi Industries Limited | 859.94 Million INR | 8.025% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 92.116% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -445.564% |
| Themis Medicare Limited | 764.96 Million INR | -3.396% |
| Unichem Laboratories Limited | 931.91 Million INR | 15.128% |
| Vaishali Pharma Limited | 119.13 Million INR | -563.9% |
| Wanbury Limited | 1.1 Billion INR | 28.479% |
| Windlas Biotech Limited | -273.04 Million INR | 389.678% |
| ZIM Laboratories Limited | 983.6 Million INR | 19.588% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 119.045% |
| Ipca Laboratories Limited | 11.41 Billion INR | 93.071% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.091% |
| Venus Remedies Limited | -267.7 Million INR | 395.456% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 78.585% |
| Divi's Laboratories Limited | -39.77 Billion INR | 101.989% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 115.779% |
| Mankind Pharma Limited | -1.74 Billion INR | 145.239% |
| Sequent Scientific Limited | 4.17 Billion INR | 81.072% |
| Laurus Labs Limited | 24.35 Billion INR | 96.753% |
| Neuland Laboratories Limited | -214.05 Million INR | 469.497% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 71.965% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 118.457% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 79.782% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 417.911% |
| Wockhardt Limited | 18.27 Billion INR | 95.671% |
| Bal Pharma Limited | 1.26 Billion INR | 37.404% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 93.875% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 168.317% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 315.785% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 114.361% |
| Shilpa Medicare Limited | 9.06 Billion INR | 91.279% |
| Valiant Laboratories Limited | 649.9 Million INR | -21.701% |
| Ajanta Pharma Limited | -954.9 Million INR | 182.829% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -165.79% |
| Granules India Limited | 9.28 Billion INR | 91.483% |
| Medicamen Biotech Limited | 160.31 Million INR | -393.361% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -1611.577% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.839% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 97.515% |
| NATCO Pharma Limited | -5.81 Billion INR | 113.597% |
| Suven Life Sciences Limited | -1.63 Billion INR | 148.444% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 59.081% |
| Strides Pharma Science Limited | 23.25 Billion INR | 96.599% |
| Indoco Remedies Limited | 6.47 Billion INR | 87.787% |
| Alpa Laboratories Limited | 35.36 Million INR | -2136.623% |
| Lasa Supergenerics Limited | 205.79 Million INR | -284.325% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 183.981% |